Evommune, Inc. Outstanding Bonds Bonds
Note series still outstanding, nearest maturity first. Terms are from each offering's final pricing term sheet on SEC EDGAR; a reopening of the same CUSIP adds to its principal. Interest per payment = principal × coupon ÷ payments per year. Outstanding = principal issued minus each filed exchange, tender, redemption or conversion; it is (m) where the retired amount was not filed. Interest per payment uses the outstanding principal.
| Notes | Principal issued | Outstanding | Coupon | Trade date | Issue / settlement date | Maturity date | Interest payment dates | Interest per payment | Annual coupon interest | Optional redemption | Retired | Priced |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |